PTN Palatin Technologies
- 1.1100
- 0.00000.00%
- 1.1199
- +0.0099+0.89%
Palatin Technologies News
Palatin Technologies: Positive Phase 2b Results and Strategic Growth Opportunities Justify Buy Rating
Express News | Palatin Technologies Inc - Bremelanotide Well Tolerated With No Serious Adverse Events
Express News | Palatin Announces Positive Phase Iib Breakout Study Results in Patients With Type 2 Diabetic Nephropathy
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients With Type 2 Diabetic Nephropathy
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target
Palatin Techs Analyst Ratings
Palatin Technologies Shares Are Trading Higher After the Company Announced the Completion of Enrollment in Its Phase 2 Study of PL8177.
Express News | Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist Pl8177 in Ulcerative Colitis
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Q1 2025 Palatin Technologies Inc Earnings Call
Palatin Technologies Shifts Focus to Obesity Treatments
Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript Summary
Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript
Palatin Technologies: Strategic Focus on Obesity and Diversified Pipeline Justifies Buy Rating
Palatin Technologies | 10-Q: Q1 2025 Earnings Report
Express News | Palatin Technologies Inc: To Advance Obesity Programs and Start Multiple Clinical Trials in 2025
Palatin Technologies: Actively Engaged With Multiple Potential Funding Sources for Future Operating Cash Needs >PTN
Express News | Palatin Technologies Q1 EPS USD -0.39
Press Release: Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
No Data